The Promising Treatment CTP-543: Once or Twice Daily?
Concert Pharmaceutical's research team has recently initiated open label trials to determine the optimal dosage rate of the compound CTP-543 for those with
Concert Pharmaceuticals Reports on New Treatment for Alopecia Areata
Concert Pharmaceuticals is a leading company for the development of treatments similar to topical tofacitinib and topical ruxolitinib, both of which are
Dr. Donovan Article: Topical JAK inhibitors for Treating AA in Children/Adolescents
For the latest research article from Dr. J. Donovan, please click on this link: Canaaf June 2017 Thank you Dr. Donovan for